Figure 1From: Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model Viral RNA levels in vaccinated macaques (A71, A75, A76 and A78; group A: blue lines) and contemporaneous controls given ASO2 A adjuvant only (B234-237; group C: red lines) after challenge with 10MID 50 SHIV sbg and followed for twenty weeks. Back to article page